TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix Pharmaceuticals announces that the European marketing authorization application for TLX101-Px, its PET imaging agent for glioma, has been validated and accepted for review, initiating a 210-day assessment phase. The product addresses a critical unmet need in brain cancer diagnostics by enabling better differentiation between tumor progression…